271 related articles for article (PubMed ID: 10424320)
1. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19).
Sandwall P; Lo MW; Jonzon B; Dalén P; Furtek C; Ritter M; Alván G; McCrea J; Sjöqvist F
Eur J Clin Pharmacol; 1999 Jun; 55(4):279-83. PubMed ID: 10424320
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
3. Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin A; Arns PA; Richards WO; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1998 Jul; 64(1):8-17. PubMed ID: 9695714
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
5. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia.
Marandi T; Dahl ML; Rägo L; Kiivet R; Sjöqvist F
Eur J Clin Pharmacol; 1997; 53(3-4):257-60. PubMed ID: 9476041
[TBL] [Abstract][Full Text] [Related]
6. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
7. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
Wennerholm A; Nordmark A; Pihlsgård M; Mahindi M; Bertilsson L; Gustafsson LL
Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
[TBL] [Abstract][Full Text] [Related]
9. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
Caraco Y; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
[TBL] [Abstract][Full Text] [Related]
10. Formation of meprobamate from carisoprodol is catalysed by CYP2C19.
Dalén P; Alvan G; Wakelkamp M; Olsen H
Pharmacogenetics; 1996 Oct; 6(5):387-94. PubMed ID: 8946470
[TBL] [Abstract][Full Text] [Related]
11. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
13. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.
Evans DA; Krahn P; Narayanan N
Pharmacogenetics; 1995 Apr; 5(2):64-71. PubMed ID: 7663530
[TBL] [Abstract][Full Text] [Related]
14. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
[TBL] [Abstract][Full Text] [Related]
15. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
16. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L
Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476
[TBL] [Abstract][Full Text] [Related]
17. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.
Ward SA; Walle T; Walle UK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1989 Jan; 45(1):72-9. PubMed ID: 2910639
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
Masimirembwa CM; Gustafsson LL; Dahl ML; Abdi YA; Hasler JA
Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982
[TBL] [Abstract][Full Text] [Related]
19. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity.
Hellman K; Roos E; Osterlund A; Wahlberg A; Gustafsson LL; Bertilsson L; Fredrikson S
Br J Clin Pharmacol; 2003 Sep; 56(3):337-40. PubMed ID: 12919185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
